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Abstract
The lysine 58 cleaved and truncated variant of b2-microglobulin (DK58-b2m) is conformationally
unstable and present in the circulation of a large percentage of patients on chronic hemodialysis,
suggesting that it could play a role in the b2-microglobulin (b2m) amyloid fibrillogenesis associated
with dialysis-related amyloidosis (DRA). However, it has yet to be detected in the amyloid deposits of
such patients. Here, we extracted amyloid fibrils, without denaturation or additional purification, from
different amyloidotic tissues of two unrelated individuals suffering from DRA, and characterized them
by high-sensitivity bidimensional gel electrophoresis (2D-PAGE), immunoblotting, MALDI time-of-
flight mass spectrometry, and protein sequencing. To confirm whether or not this species could be
identified by our proteomic approaches, we mapped its location in 2D-PAGE, in mixtures of pure DK58-
b2m, and extracts of amyloid fibrils from patients, to a discrete region of the gel distinct from other
isoforms of b2m. Using this approach, the two known principal isoforms found in b2m amyloid were
identified, namely, the full-length protein and the truncated species lacking six N-terminal amino acid
residues (DN6-b2m). In contrast, we found no evidence for the presence of DK58-b2m.
Keywords: dialysis related amyloidosis; amyloid fibrils; proteolized variants of b2-microglobulin;
proteomics
In 1985 the team led by Fumitake Gejyo discovered that
b2-microglobulin (b2m) is the protein that generates
amyloid fibrils in dialysis-related amyloidosis (DRA)
(Gejyo et al. 1985). The pathogenesis of this amyloidosis,
considered to be a prototypical man-made protein mis-
folding disease (Dobson 2006), is certainly related to the
defective renal clearance of b2m in chronic kidney disease
and its inefficient removal from the circulation by dialysis
(Yamamoto and Gejyo 2005). The basis of the disease is
most likely based on the elevated concentration of b2m,
its misfolding propensity (Corazza et al. 2004), and its
collagen-philia (Relini et al. 2006). While full-length b2m
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is an ubiquitous and major constituent and an important
component of these amyloid fibrils, it has been demon-
strated that a N-terminal truncated species lacking six
residues (DN6-b2m) is present and that this species, with
its high tendency to aggregate, could represent an influen-
tial element in the process of aggregation (Linke et al.
1987; Bellotti et al. 1998; Esposito et al. 2000). To date no
other chemical species of b2m have been consistently
reported in natural fibrils and products of mild oxidation
and Asn deamidation that are detectable in natural fibrils
have not attracted particular interest as a possible agent in
b2m amyloidogenesis. However, another variant of b2m,
DK58-b2m, has been discovered in the sera of ;40% of
patients undergoing chronic hemodialysis (Corlin et al.
2005). DK58-b2m was discovered in 1987 by Nissen’s
group (Nissen et al. 1987) and it can be generated by
incubating b2m with patient sera at 37°C. Activated C1s is
the proteolytic enzyme capable of cleaving the protein at
Lys58, giving rise to a new b2m species in which the two
interrupted polypeptides corresponding to the sequences
1–58 and 59–99 are still covalently connected through the
disulfide bridge at Cys 25–80. An additional cleavage, due
to carboxypeptidase B-like activity, occurs in plasma and
causes the removal of Lys58, yielding the N-terminal
cleaved b2m species (Nissen et al. 1990). DK58-b2m so
far has only been directly detected in blood samples from
hemodialysis patients, but its conversion from parent b2m
was also found to be accelerated by incubation with sera
from patients suffering from autoimmune diseases, AIDS,
and small-cell lung cancer (Plesner and Wiik 1979; Nissen
et al. 1984; Bhalla et al. 1985). DK58-b2m represents
conformer variants of b2m that may be important for the
elucidation of the molecular basis of DRA amyloidosis. In
vitro studies have demonstrated that in comparison with the
intact protein, this species is highly destabilized and at
37°C, in the presence of 10% b2m fibrillar seeds, forms
aggregates with amyloid characteristics in <1 h (Heegaard
et al. 2005). In solution, DK58-b2m populates an inter-
mediate state of folding (Mimmi et al. 2006) that specif-
ically binds Congo red and displays a high propensity to
aggregate (Heegaard et al. 2001). The role of DK58-b2m in
amyloid deposition in vivo is, however, uncertain, since in
natural amyloid fibrils this species has never been detected
by classical amino acid sequencing or by the combination
of two-dimensional (2D) gel electrophoresis and mass
spectrometry (Stoppini et al. 2005). However, the effective-
ness of this second approach in detecting DK58-b2m has
never been ascertained. Prompted by these findings and our
prior observations concerning potential loss of b2m frag-
ments during typical amyloid extraction/denaturation pro-
cedures (Stoppini et al. 2000), we sought to establish
whether or not proteomics approaches could identify the
DK58-b2m variant by comparing b2m isoforms in ex vivo
amyloid fibrils (i.e., fibrils obtained from patients) isolated
in ‘‘native’’ fibrillar conformation from amyloidotic tissues
of two patients with dialysis-related amyloidosis, in the
absence and presence of added pure DK58-b2m.
Results and Discussion
Amyloid fibrils were isolated under nondenaturing con-
ditions, without additional purification, from two dif-
ferent types of periarticular tissues derived from two
unrelated individuals affected by dialysis-related amyloi-
dosis. The morphology and dimensions of the fibrils were
first compared by atomic force microscopy (AFM). The
fibrils shown in Figure 1A were extracted from the
shoulder capsule of a British patient, while the fibrils in
Figure 1B were extracted from the amyloid material
surrounding the femoral head of an Italian patient; both
patients underwent hemodialysis, in the latter case for
more than 20 yr. In both preparations the fibrils form
bundles, in which adjacent fibrils are often intertwined or
partially interconnected. Fibrils are more distinct in the
sample extracted from the British patient, while a closer
interconnection among fibrils is observed in the sample
extracted from the Italian patient. However, the latter
contains a larger amount of amorphous material, clearly
visible in the background; in this case, fibrils embedded
in amorphous material could result somewhat ‘‘glued’’
one to another. In contrast, amorphous material is nearly
Figure 1. Tapping mode AFM images (left, height data; right, amplitude
data) of natural amyloid fibrils extracted from the shoulder capsule of a
British patient (A) and from the amyloid material surrounding the femoral
head of an Italian patient (B). Scan size, 1.2 mm; Z range, 11 nm (A),
22 nm (B).
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absent in the sample extracted from the British patient.
Fibrils height, measured from the corresponding height in
a cross-section of AFM images, is 2.2 6 0.1 nm for the
British patient and 2.3 6 0.3 nm for the Italian patient;
these values are comparable within experimental error.
As the sample was dried for AFM imaging in air, the
measured fibril heights are smaller than those expected to
correspond to fully hydrated conditions.
Extracted material of both samples was directly ana-
lyzed in 2D-PAGE and immunoblotting with polyclonal
anti-b2m antibodies. In Figure 2, A and B the immuno-
blots of amyloid fibrils obtained from the Italian and
British patients are shown, respectively. In order to
identify all of the spots corresponding to b2m, the blots
were immunostained with polyclonal antiserum against
human b2m. The samples showed marked electrophoretic
heterogeneity with respect to molecular weight and
especially for pI.
We have assigned the single spots detected by the
antibody to the spots visualized in a correspondent 2D gel
stained with Coomassie. In this way, we have identified
several spots at ﬃ12 kDa and slightly lower molecular
weight regions that are focused in a pH range from 4.0 to
6.2 that can be assigned to different isoforms of b2m.
These spots were processed for the chemical character-
ization. The N-terminal sequence enabled the identifica-
tion of the spots 1–6 as full-length b2m and spots 7–9 as
the truncated form designated as DN6-b2m. These data
are consistent with their respective predicted molecular
masses of 11,731 and 11,007 Da. MALDI-TOF analysis
of protein spots digested with protease Glu-C confirmed
these assignments in further detail regarding the length
and post-translational modifications. Results indicated
that all spots terminate at Met 99 and that the main
components are not cleaved at the C-terminal. Spot
number 3 presents a partial deamidation of Asn42 and a
partial oxidation of Met 99 to methionine sulphone. Spot
numbers 4, 5, and 6 present different degrees of Asn17
and Asn42 deamidation, and Met99 partial oxidation.
Spot numbers 7, 8, and 9 are characterized by different
degrees of Asn17 and Asn42 deamidation, as well as
Met99 oxidation.
There is a very close correspondence between spot
patterns obtained from the fibrils of the Italian and the
British patients. In order to identify a peptide possibly
derived from DK58-b2m we searched all of the spots for
the tryptic peptide corresponding to the sequence 59–75
with a N-terminal Asp residue and a molecular mass of
2203 Da (i.e., the N-terminal tryptic peptide from the
B-chain of DK58-b2m), but no such peptide was detectable.
The pattern observed in our natural amyloid fibrils (Fig. 2)
is remarkably consistent with that reported by Argiles and
colleagues in 1995 in a study in which the natural b2m
fibrils were analyzed by 2D-PAGE and immunoblotting
(Argiles et al. 1995). In order to provide an immediate
comparison of those data with our results, the 2D gel elec-
trophoresis reported by Argiles is reproduced here with per-
mission in Figure 3. In the case reported by Argiles, several
species of b2m with heterogeneous isoelectric points were
distributed along the axis of a common molecular weight
Figure 2. Western blot immunostained with anti b2m antibodies of bidimensional electrophoresis of the following material: (A)
Fibrils extracted from the amyloid material surrounding the femoral head of the Italian patient; (B) fibrils extracted from the shoulder
capsule of the British patient; (C) mixture 1:1 of amyloid fibrils of the Italian patient and DK58-b2m.
Proteomic of b2-microglobin natural fibrils
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of ;12 kDa. These b2m species appear to correspond to
spots obtained in our specimens and are indicated in
Figure 2, A and B as spots 1–6 that correspond to the full-
length b2m (Fig. 2). The spots of isoelectric point and
slightly lower molecular mass (Fig. 3) most likely corre-
spond to spots 7 and 8 in our sample (Fig. 2A,B) that we
have assigned to DN6-b2m.
Interestingly, Argiles et al. (1995) did not report the
presence of DN6-b2m nor DK58-b2m in their purified
preparations. One explanation for the apparent absence of
DN6-b2m, as we have previously suggested (Stoppini et al.
2000), could be related to the aqueous solvent used in the
purification steps. In fact, purified DN6-b2m, in nondena-
turing aqueous solutions, has a strong propensity to self
aggregate and irreversibly precipitate (Esposito et al. 2000).
To validate that our approaches, reagents, and proce-
dures could identify the DK58-b2m variant if present, we
spiked increasing concentrations of the purified protein
into amyloid fibrils of the Italian patient. Figure 2C
shows that DK58-b2m is well visualized in Western blots
of 2D-PAGE, migrating as three discrete spots (numbered
10, 11, and 12) that localize in a region of the gel distinct
from the other isoforms. Indeed, the sensitivity of the
procedure allowed detection of 1 ng of DK58-b2m.
Notably, as mentioned above, the spots generated by
DK58-b2m are completely absent in amyloid fibrils to
which no pure protein was added (Figs. 2A,B), even after
prolonged exposure of the blots.
The isoelectric point and molecular weight species of
Figure 2C are consistent with the properties of a reduced
DK58b2-m. In fact, the predicted pIs of peptides 1–57
(A-chain) and 59–99 (B-chain) are 6.3 and 5.13, respec-
tively, while the molecular weights are 6531 and 5089 Da.
The corresponding spots in a 2D-gel analysis of
reduced and S-alkylated DK58-b2m were stained by
Coomassie blue, excised, and digested with trypsin.
Two specific peptides of the A-chain (amino acids 1–57,
peptide 20–41 [M+H+]: 2555.87 Da) and of the B-chain
(amino acids 59–99, peptide 1–23 [M+H+]: 2999.28 Da)
were used as indicators of the origins of the spots.
Figure 4 shows different portions of the mass spectra of
the four numbered spots excised from the Coomassie-
stained gel. Despite differences caused by different pI-
resolution, spots 2 and 9 of Figure 4 correspond to spots
12 and 10, respectively, of the immunoblot in Figure 2C.
The two additional spots that were identified by mass
spectrometry in Figure 4, i.e., spots 3 and 8, correspond to
the intermediate material in Figure 2C represented by the
splitting of spot 12 and the distinct intermediary spot 11.
The exact correspondence between the spots in the two
2D experiments cannot be given more precisely, but the
data unequivocally demonstrate that all material origi-
nates from DK58-b2m. Thus, the marked peaks were only
found in spectra of the indicated spots. They were also
found in the intermediary material (spots 3 and 8), and
thus, both chains have a fraction of material with changed
pI compatible with deamidation species as mentioned
above for the b2m species found in amyloid extracts. The
main result of these experiments is that we show that
the DK58-b2m species are well resolved in a 2D gel and
that no material corresponding to these spots appears in
the amyloid fibril extracts from the two patients exam-
ined. The sensitivity of the 2D-PAGE immunoblotting
method allows the detection of 1 ng of DK58-b2m loaded
in the gel, i.e., a limit corresponding to about 1% of
the amount of material loaded for the immunoblots (data
not shown).
Conclusion
In this study we report new data regarding the protein
composition of natural amyloid fibrils created by b2m in
two different patients suffering from DRA. Particular
attention was paid to the identification of the b2m species
known as DK58-b2m, since this b2m conformer is con-
formationally unstable and putatively amyloidogenic in
vitro (Heegaard et al. 2005), and because it was recently
isolated and quantified in serum of patients submitted to
hemodialysis (Corlin et al. 2005).
Our data demonstrate that, at least in the two patients
studied here, DK58-b2m is not detectable in natural
fibrils by a highly sensitive procedure such as immuno-
blotting with chemiluminescence visualization of 2D-
PAGE separated extracted components. Through our
analytical approach, the specimens are minimally manip-
ulated, and therefore, we believe we can exclude artefacts
concerned with the recovery of the putative DK58-b2m
from the fibrils. The results of the analysis in which
we have artificially created a mixture of fibrils and
Figure 3. Reproduction with permission from Argiles et al. (1995). Immu-
noblotting with anti b2m antibodies of 2D-gel electrophoresis of natural
amyloid fibrils from a DRA patient (the tissue source was not specified).
Giorgetti et al.
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DK58-b2m (Fig. 2C) clearly demonstrate that this ana-
lytical procedure is highly suitable for this survey.
Even though the solubility of DK58-b2m (as in the case
of the DN6-b2m material) is significantly reduced com-
pared with full-length b2m (Mimmi et al. 2006), it is
expected to be soluble at concentrations easily detectable
in the techniques used here. Also, previous studies using
extracts from other tissues containing b2m amyloid have
shown that the pellet of material remaining after water
extraction solely contains spots representing full-length
b2m (Stoppini et al. 2005).
These findings highlight possible contradictions
between the in vivo and in vitro data. The absence in
natural fibrils of a highly unstable variant of b2m such as
DK58-b2m is actually very surprising. This species is
able to aggregate and generate fibrils at neutral pH and, if
present in plasma, would become a predominant constit-
uent of natural fibrils. In contrast, DN6-b2m, which is
highly amyloidogenic in vitro, is not detectable in plasma
(Stoppini et al. 2005), but it is a consistent component of
natural fibrils. These findings support the general impli-
cation that the process of amyloid deposition in a target
tissue requires that the fibrillogenic protein attains the
amyloidogenic conformation at the right site, at the right
time, and at the right concentration. In the case of DK58-
b2m, it is conceivable that this species could populate a
partially folded, potentially amyloidogenic conformation
in serum, but in this fluid it cannot reach the critical
concentration for aggregation and/or does not encounter
relevant cofactors required for fibrillogenesis (Relini
et al. 2006). Under such conditions, we can speculate
that it may be more susceptible to degradation than to
amyloid deposition. The identification of degradative
pathways of amyloidogenic proteins that do not lead to
fibril formation and deposition is of great interest and has
implications for the interpretation of amyloid pathogen-
esis and will be important for consideration regarding
new therapeutic strategies.
Materials and methods
Protein extraction from ex vivo fibrils
Amyloid fibrils were isolated from amyloidotic unfixed frozen
(80°C) femoral head tissue of an Italian patient and shoulder
synovial tissue of an unrelated UK patient, with DRA, obtained
after surgery with informed consent. Intense specific staining
(Tennent 1999) of the amyloid deposits in tissue sections with
polyclonal anti b2m antibodies confirmed that b2m was the major
fibril protein. The fibrils were prepared independently by two
researchers, by classical water extraction (Pras et al. 1968),
according to previously described procedures (Tennent 1999;
Relini et al. 2006) that differed by the use of ultracentrifugation
(60,000g for 30 min; Beckman L8–704, Beckman Coulter S.p.A)
and inclusion throughout of PMSF in the femoral head preparation
(Relini et al. 2006). The presence of typical amyloid fibrils in the
final isolates was confirmed by red-green dichroism/green-bire-
fringence in cross-polarized light microscopy after staining with
alkaline alcoholic Congo red and a characteristic fibrillar appear-
ance in negative stain TEM. Fibril fractions containing the greatest
abundance of amyloid, in each preparation, were pooled and
lyophilized (Modulyo EF4, Edwards High Vacuum).
Atomic force microscopy
For AFM imaging, the amyloid fibril preparation obtained by
the water extraction procedure was diluted 60 times; a 20-mL
Figure 4. Spot identification by 2D-gel electrophoresis of purified DK58-b2m and MALDI-TOF MS analysis of tryptic spot digests. A
portion of the 2D gel is shown with pI and molecular weight values indicated. The MS analyses of the numbered spots are shown in the mass
spectra, focusing on the diagnostic peptides for the A-chain (amino acids 1–57) and the B-chain (amino acids 59–99). The A-chain peptide
(2555.9 Da) is found only in the spectra of spots 2 and 3, and the B-chain peptide (2999.3 Da) is found only in the spectra of spots 8 and 9.
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aliquot of the diluted sample was deposited on freshly cleaved
mica and dried under mild vacuum. Images were acquired in
tapping mode in air using a Dimension 3000 microscope
(Digital Instruments–Veeco), equipped with a ‘G’ scanning head
(maximum scan size 100 mm) and driven by a Nanoscope IIIa
controller. Single-beam uncoated silicon cantilevers (type
OMCL-AC, Olympus, and RTESP, Veeco) were used. Fibril
height was measured from the corresponding height in cross-
section in the AFM images. The drive frequency was 300 kHz;
the scan rate was between 0.3 and 0.5 Hz. Vertical displace-
ments were calibrated measuring the depth of grating notches
(180 nm) and the half-unit cell steps (1 nm) obtained by treating
freshly cleaved mica with hydrofluoric acid. The horizontal
displacements of the piezoelectric tubes were calibrated using a
3-mm pitch diffraction grating.
DK58-b2m preparation
DK58-b2m was derived from wild-type b2m purified from a
pool of urine from nephropathy patients, as described previously
(Nissen et al. 1987). By mass spectrometry, the molecular mass
of the purified protein was in agreement with the theoretical
value of 11,619 Da.
Two-dimensional polyacrylamide gel electrophoresis
(2D-PAGE)
The first dimensional protein separation was performed using
Immobiline Dry Strips, pH 3–10 (nonlinear gradient). The
samples for Coomassie staining and blotting detection, respec-
tively, were conditioned in a rehydration buffer: 8 M urea, 4%
CHAPS, 65 mM DTE, 0.8% ampholine, and 0.002% bromo-
phenol blue. Isoelectric focusing was performed on an IPGphor
system (Amersham Biosciences). For the Coomassie staining, a
standard concentration of 200 mg of protein was loaded, and for
immunoblot, the gel was generally loaded with 10 mg of protein.
The detection limit for DK58-b2m of the immunoblot was
measured by carrying out the whole procedure using progres-
sively diluted samples. After isoelectric focusing, proteins in the
IPG strips were soaked for 15 min in SDS-PAGE equilibration
buffer (50 mM Tris–HCl at pH 6.8, 6 M urea, 30% glycerol,
2% SDS) supplemented with 2% dithiothreitol. The SH groups
were subsequently blocked with a solution containing 50 mM
Tris–HCl (pH 6.8), 6 M urea, 30% glycerol, 2% SDS, 2.5%
iodoacetamide, and a trace of bromophenol blue for 5 min. The
second dimension separation was carried out in a vertical
gradient slab gel with the Laemmli-SDS discontinuous system,
using an acrylamide gel gradient of 9%–18% and 2% of cross-
linking. Proteins were visualized using the Coomassie Brilliant
blue G colloidal staining method according to previously
described methods (Oakley et al. 1980; Hochstrasser et al.
1988).
The samples for 2D-PAGE mass spectrometry consisted of
30 mg of purified DK58-b2m, which was precipitated using a 2D
cleanup kit from Bio-Rad. The precipitate was redissolved in
7 M urea, 2 M thiourea, 2% CHAPS, 0.5% IPG buffer (pH 3–11)
NL, 0.002% bromophenol blue. After rehydration of a 13-cm
Immobiline DryStrip (pH 3–11) NL (Amersham Biosciences),
the protein was focused using an IPGphor (Amersham Bio-
sciences). After isoelectric focusing, the IPG strip was soaked
2 3 15 min in SDS-PAGE equilibration buffer (50 mM Tris-HCl
at pH 8.8, 6 M urea, 2% SDS, 0.002% bromophenol blue)
supplemented with 1% dithiothreitol and 2.5% iodoacetamide.
Separation in the second dimension was carried out using a
10%–20% Criterion Tris-HCl gel (Bio-Rad) followed by visual-
ization by colloidal Coomassie staining (Colloidal Blue Staining
Kit, Invitrogen).
Immunoblotting
After 2D-PAGE, the proteins in the gel were transferred onto a
PVDF membrane as previously described (Stoppini et al. 1997).
The b2m isoforms were identified with an anti-human b2m
polyclonal antibody (Dako) using a chemiluminescent proce-
dure (ECL plus Western blotting detection reagent Amersham
Bioscience).
MALDI/MS analyses and protein sequencing
The spots stained by Coomassie were manually excised from the
gel, destained, and submitted to hydrolysis with endoproteinase
Glu-C or proteomic grade trypsin (Sigma-Aldrich) according to
the procedure previously carried out (Stoppini et al. 2005) or as
detailed below. Peptide mixtures were analyzed by MALDI-
TOF mass spectrometry using a Micromass spectrometer
(Waters) or an Ultraflex MALDI-TOF instrument (Bruker-
Daltonics). Samples were freeze-dried and then dissolved in
10 mL of 0.1% trifluoroacetic acid; 1 mL was mixed with 1 mL
of a matrix solution of a-cyano-4-hydroxycinammic acid, 5 mg/mL
in acetonitrile, 0.1% trifluoroacetic acid 7:3 (v:v), and the mixture
was applied onto the metallic sample plate and air dried. Mass
calibration was performed using a peptide standard mixture
provided by the manufacturer. The instrument was operated in
reflectron positive ion mode and spectra were acquired in the
mass-to-charge ratio range (m/z) 800–3000. All mass values are
reported as monoisotopic masses, and raw data were analyzed
using the software MassLynx 4.0 (Micromass-Waters). In addi-
tion, the sequences of proteins electroeluted from 2D-PAGE were
determined by adsorptive biphasic column technology using an
HP G1000A protein sequencer (Hewlett-Packard) as previously
detailed (Stoppini et al. 2005).
For the assignment of spots from 2D-gels as shown in Figure
4, the following procedure was applied: excised spots were
washed 30 min with 40% v/v ethanol to remove most of the
Coomassie stain and then shrunk using 100% acetonitrile
followed by evaporation to dryness in a speedvac. The dried
gel pieces were reconstituted in 50 mM NH4HCO3 with
12.5 ng/mL MS-grade trypsin (Stratagene) on ice for 45 min.
Any remaining liquid not absorbed by the gel pieces was
removed, and 20 mL 50 mM NH4HCO3 were added followed
by incubation overnight at 37°C. A total of 10 mL supernatant
were loaded on C18 stagetips (Proxeon Biosciences) equili-
brated with 0.1% TFA and washed with 1% TFA. Peptides were
eluted onto a MALDI target plate using an a-cyano-4-hydrox-
ycinnamic acid solution (6.2 mg/mL, Agilent Technologies) and
analyzed in positive ion-mode on the Ultraflex MALDI-TOF
instrument controlled by FlexControl version 2.2, build 19.
Recorded spectra were analyzed using the MoverZ freeware
from Proteometrics.
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